Axsome Therapeutics Inc. held its Annual Meeting of Stockholders on June 6, 2025. The stockholders elected Roger A. Jeffs, Ph.D., as a Class I director. The 2025 Long-Term Incentive Plan was approved. The appointment of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified. The compensation of the named executive officers was approved by a non-binding advisory vote.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Axsome Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000950170-25-083793), on June 09, 2025, and is solely responsible for the information contained therein.